Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Participate in Upcoming Investor Conferences Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen ...

Wednesday, February 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc has announced its participation in two upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Management will engage in webcast fireside chats at these events, which will be accessible live and archived for later viewing. This initiative reflects Alkermes' commitment to investor relations and transparency.
Price reaction · baseline $34.93 (2025-02-25 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is actively engaging with investors through conferences.
  • Participation in multiple investor conferences indicates strong investor interest.
  • The company showcases its commitment to transparency and communication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) announced today that management will participate in webcast fireside chats at two upcoming investor conferences.
TD Cowen 45 th Annual Health Care Conference Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET ( 2:50 p.m. GMT )
Leerink Partners Global Healthcare Conference 2025 Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET ( 3:20 p.m. GMT )
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia . Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes ' website at www.alkermes.com .

Frequently Asked Questions

What are the dates of the investor conferences?

The conferences are on March 5 and March 12, 2025.

How can I access the webcasts?

The webcasts can be accessed under the Investors tab on Alkermes' website.

What topics will Alkermes discuss at the conferences?

Alkermes will engage in fireside chats discussing its business and pipeline.

How long will the webcasts be available?

The webcasts will be archived for 14 days after the events.

ShareAdd on Google
Tags: ALKS Viatris Investor Conferences Healthcare Alkermes investor conferences TD Cowen Leerink Partners biopharmaceuticals
Last updated: Feb 26, 2025

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
N1539Phase 2
Hysterectomy →

Catalyst track record

+29%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →